Navigation Links
Esperance Pharmaceuticals Completes $7.5 Million Series B Financing
Date:6/1/2011

BATON ROUGE, La., June 1, 2011 /PRNewswire/ -- Esperance Pharmaceuticals, Inc. today announced the first closing of a $7.5 million Series B financing. Proceeds from the Series B will support further clinical development of EP-100, the lead cancer-targeting drug candidate from Esperance's Cationic Lytic Peptide (CLYP™) platform technology and the continued expansion of the Company's pipeline. Sanofi led the Series B funding with an investment of $4.5 million, which includes $1.5 million in clinical and regulatory services to support further development of EP-100. In addition, all existing institutional investors in Esperance -- Louisiana Fund I, Themelios Ventures, Research Corporation Technologies and Advantage Capital Partners/Louisiana Technology Fund -- as well as current and new private investors participated in the syndicate.

"We are extremely pleased to welcome Sanofi as an investor and strategic partner to Esperance and we are grateful for the unanimous, continued support of our current investors," said Hector Alila, PhD, President and CEO of Esperance Pharmaceuticals. "We believe the quality of this syndicate speaks directly to the significant potential of our pipeline and we look forward to being able to deliver on the clinical promise of EP-100 and our CLYP™ platform technology."

"Esperance has made great strides over the last few years building an impressive, proprietary technology platform with broad-based application and bringing forth strong therapeutic candidates to its pipeline," said Joseph F. Lovett, Chairman of the Board of Esperance and Managing General Partner at Louisiana Fund I. "I am pleased to continue to be part of the progress moving forward and I believe the caliber of investors involved in this syndicate, particularly Sanofi, is a significant accomplishment for Esperance and speaks to the strength of the growing biotech community in this reg
'/>"/>

SOURCE Esperance Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. First Candidate from Esperances Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  HyGreen, Inc., a leader in hand hygiene monitoring, ... Medical, a subsidiary of Ascendis Health Limited, in ... year, hundreds of millions of patients around the world ... transmitted from patient to patient via the unwashed hands ...
(Date:1/23/2015)... Companies, Inc. (ICBU) has repositioned itself as a holding company ... foothold in the hydroponic, hemp and medical marijuana sectors. By ... the sector, and recently partnering with the Chippewa Tribe Nation ... marijuana, iMD is committing to bring its vision to the ...
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin ... a Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities ... update for shareholders detailing why a "YES" vote to increase ... Shareholders, As we reflect upon the 2014 fiscal ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
... Tool Detects Risk for Undiagnosed Diabetes, Plus: ... ALEXANDRIA, Va., April 28 A highly detailed,mathematical ... whether they likely have the disease and can ... associated with this now,epidemic illness, according to studies ...
... Fighting Blindness ... OWINGS MILLS, Md., April 27 Scientists employing a ... blind from,a condition known as Leber congenital amaurosis (LCA) -- ... trial, which was,funded in part by the Foundation Fighting Blindness, ...
Cached Medicine Technology:Drug Combo Could Lower Diabetes Complications and Costs 2Drug Combo Could Lower Diabetes Complications and Costs 3Drug Combo Could Lower Diabetes Complications and Costs 4Drug Combo Could Lower Diabetes Complications and Costs 5Gene Therapy Provides Vision to People who Were Nearly Blind 2
(Date:1/22/2015)... Florida (PRWEB) January 22, 2015 IsoComforter, Inc. ... therapy machine with patented IsoTube design to treat specific body ... introduced the most progressive and easy to use patented cold ... post-operative and sports related orthopedic and muscle injuries. IsoComforter ...
(Date:1/22/2015)... Payday lending practices in four southern states worsen ... to the states that permit them, according to a ... Race and Wealth. , While they generate hundreds of ... the same time substantially depress economic activity, according to ...
(Date:1/22/2015)... As interest in the value of spiritual support as ... Rev. Eric J. Hall , president and CEO of the ... the keynote speaker on January 27 at an international summit ... The conference, “Hope and Resilience: Innovative and Interdisciplinary Spiritual Care,” ...
(Date:1/22/2015)... January 22, 2015 Compare-autoinsurance.org has released a new ... by an auto insurance policy . , Some types ... Clients should check the newly released blog post to see if ... and dangerously damaged vehicles are some of the cars that cannot ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Step into ... at the Science Museum of Virginia. Wicked Plants, the ... Wicked Plants unearths 75 poisonous, carnivorous and diabolical plants ... each room to uncover the biochemical, physical and neurological ...
Breaking Medicine News(10 mins):Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... GLASSBORO, N.J., Aug. 25 Getting a firmer, healthier, better-looking body -- in ... a fitness plan that will truly help you reach your personal goals. , ... , , , An ... you will dedicate to achieving your fitness goals and stick with it! , ...
... , Study Suggests Division, Ambivalence and Hesitancy ... ANN ARBOR, Mich., Aug. 25 Americans lack confidence that healthcare ... to a survey released today by the Thomson Reuters. , ... healthcare reform, addresses a wide range of issues including the cost ...
... Most OTC hemorrhoid ... your hemorrhoids faster. , ... York, NY (PRWEB) August 26, 2009 -- Many drug companies desperately do not want revealed ... damage. "Steroid creams in particular may cause permanent damage or ulceration of perianal skin," states ...
... , , Updated Report ... , , LANDOVER, Md., Aug. 25 ... conditions, the school-house is a focal point for managing their diseases. ... and Allergy Foundation of America (AAFA) has released a report assessing ...
... ONCOLOGY: Human breast cancer hit for six: key role for ... and colleagues, at the University of Colorado School of Medicine, ... mouse models and analysis of human cells, implicating the protein ... that plays a central role in development, is not expressed ...
... , , OMAHA, ... its private equity sponsor, Diamond Castle Holdings and the Company,s Management ... debt and renegotiated favorable new terms and conditions with its banking ... As a result of this transaction, overall debt for YORK ...
Cached Medicine News:Health News:Why Weight for a Better Body? 2Health News:Thomson Reuters Survey: Americans Skeptical that Healthcare Reform Will Improve Quality or Affordability 2Health News:Thomson Reuters Survey: Americans Skeptical that Healthcare Reform Will Improve Quality or Affordability 3Health News:Introducing anuleaf AD, a New FDA-Approved Hemorrhoid Treatment 2Health News:Deja Vu for Six States on Annual Asthma & Allergy Honor Roll 2Health News:Deja Vu for Six States on Annual Asthma & Allergy Honor Roll 3Health News:JCI table of contents: Aug. 24, 2009 2Health News:JCI table of contents: Aug. 24, 2009 3Health News:JCI table of contents: Aug. 24, 2009 4Health News:JCI table of contents: Aug. 24, 2009 5Health News:JCI table of contents: Aug. 24, 2009 6Health News:YORK Label Announces Continued Investment in the Company 2
... Double Bundle PCL Guides were developed to ... necessary in arthroscopic double bundle PCL reconstruction. ... anterolateral and posteromedial femoral tunnel sockets drilled ... anterolateral tunnel placement a guide can be ...
... The Flexible Digital Implant offers surgeons ... for the correction of a hammertoe deformity. ... grade silicone and is designed for the ... five. The Futura FDI features an anatomic ...
... The primary objective of the BioPro ... arthroplasty that will relieve pain and restore ... the foot undisturbed. The procedure used to ... minimal bone resection. , ,The design for ...
... Ad-Techs Intraoperative Electrodes share ... electrodes. The main difference is ... discs are numbered to assist ... electrodes are designed for use ...
Medicine Products: